中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (6): 1132-1136.doi: 10.3969/j.issn.1673-8225.2011.06.041

• 干细胞临床实践 clinical practice of stem cells • 上一篇    下一篇

自体造血干细胞移植治疗恶性淋巴瘤后大剂量白细胞介素2过继免疫对长期生存的影响

刘  昊1，2，郭  智1   

  1. 1解放军北京军区总医院血液科，北京市  100700
    2 安徽医科大学第一临床学院，安徽省合肥市  230032
  • 收稿日期:2010-08-16 修回日期:2010-10-10 出版日期:2011-02-05 发布日期:2011-02-05
  • 通讯作者: 郭智，硕士，副主任医师，副教授，解放军北京军区总医院血液科,北京市 100700 gzdd2004@yahoo.com.cn
  • 作者简介:刘昊★，女，1986年生，安徽省阜阳市人，汉族，安徽医科大学在读硕士，主要从事肿瘤生物治疗及造血干细胞移植的研究。 liuhao.025@gmail.com

Effects of high-dose interleukin-2 adoptive immunotherapy on long-term survival after autologous hematopoietic stem cell transplantation for treating malignant lymphoma

Liu Hao1, 2, Guo Zhi1   

  1. 1Department of Hematology, General Hospital of Beijing Military Area Command of Chinese PLA, Beijing  100700, China
    2First Clinical College, Anhui Medical University, Hefei  230032, Anhui Province, China
  • Received:2010-08-16 Revised:2010-10-10 Online:2011-02-05 Published:2011-02-05
  • Contact: Guo Zhi, Master, Associate chief physician, Associate professor, Department of Hematology, General Hospital of Beijing Military Area Command of Chinese PLA, Beijing 100700, China gzdd2004@yahoo.com.cn
  • About author:Liu Hao★, Studying for master’s degree, Department of Hematology, General Hospital of Beijing Military Area Command of Chinese PLA, Beijing 100700, China; First Clinical College, Anhui Medical University, Hefei 230032, Anhui Province, China liuhao.025@gmail.com

PDF

439

被引次数

11

摘要：

背景：过继免疫治疗是目前肿瘤免疫治疗的热点，白细胞介素2是一种具有多种生物学活性的细胞因子，在机体的抗肿瘤免疫中起到重要作用。
目的：评价比较淋巴瘤自体造血干细胞移植治疗后应用与不应用大剂量白介素2行免疫治疗的临床疗效。
方法：回顾分析30例恶性淋巴瘤患者(治疗组)自体造血干细胞移植后行大剂量白细胞介素2 治疗，与随机挑选30例患者(对照组)自体造血干细胞移植后未行白细胞介素2治疗进行对比，检测两组患者外周血T淋巴细胞亚群，观察两组免疫功能的变化，并对所有患者进行随访观察。
结果与结论：自体造血干细胞移植后白细胞介素2治疗组外周血T淋巴细胞亚群CD3+、CD4+、CD8+、CD4+/CD8+水平明显提升。随访结束时统计复发率：治疗组13.3%，对照组26.7%；中位生存期：治疗组14~98 (42±2)个月，对照组8~78 (28±2)个月。提示恶性淋巴瘤自体造血干细胞移植后行大剂量白细胞介素2治疗能提高患者的免疫功能，减少移植后复发率，并有望延长生存期。

关键词: 恶性淋巴瘤, 自体造血干细胞移植, 白细胞介素2, 过继免疫治疗, 长期生存

Abstract:

BACKGROUND: Adoptive immunotherapy is a hot focus in tumor immunotherapy. Interleukin-2 (IL-2) is a cytokine with multiple kinds of biological activities, and plays an important role in anti-tumor immunity in the body.
OBJECTIVE: To assess clinical efficacy of high-dose IL-2 adoptive immunotherapy after autologous hematopoietic stem cell transplantation (AHSCT) of malignant lymphoma.
METHODS: A total of 30 malignant lymphoma patients treated with high-dose IL-2 after AHSCT (therapy group) were compared with 30 randomly selected malignant lymphoma patients without high-dose IL-2 therapy after AHSCT. T lymphocyte subsets in peripheral blood of both groups were detected. Changes in their immune function were observed, and all patients were followed up.
RESULTS AND CONCLUSION: There was an increase in T lymphocyte subsets CD3+, CD4+, CD8+, CD4+/CD8+ in peripheral blood of the therapy group following AHSCT. The recurrence rate at the end of follow up: 13.3% in therapy group, and 26.7% in control group; median survival time: 14-98 (42±2) months in therapy group, and 8-78 (28±2) months in control group. Results indicated that high-dose IL-2 therapy of malignant lymphoma patients after AHSCT may improve immune function, reduce recurrence rate after transplantation and prolong survival time.

中图分类号: